HR Execs on the Move


 
Adloox is the only Premium Ad Verification company. Created in 2009, Adloox offers the deepest Brand Safety, Fraud and Viewability data analysis in the digital market today. Adloox has developed its own Auditing Index, allowing advertisers, agencies, trading desks and ad networks to optimise their campaign efficiency on the fly, and detect the most granular domain/site level inefficiencies such as fraud, iframe nesting, bot detection and more.... all in real time. With Offices in New York, London, and Paris, and Clients across Europe, the US, Latin America, Africa and Apac, Adloox track and verify billions of impressions for our clients, through ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.adloox.com
  • 205 E 42nd Street
    New York, NY USA 10017
  • Phone: 917.763.0036

Executives

Name Title Contact Details

Similar Companies

Zapflow

Cloud-based productivity tool for professional investors to manage dealflow every day. #Dealflow #VentureCapital #VC #Saas #Productivity

Kinetic IS

Kinetic IS is a Copper Cliff, ON-based company in the Software & Internet sector.

Unsupervised

Unsupervised is on a mission to empower business operators to make the optimal decision with the data available to them. As the premier automated analytics platform for enterprise, Unsupervised transforms raw data into a continuous stream of easy-to-act-on insights that positively impact the KPIs and financial metrics that businesses care about most.

Net Access

Net Access is an industry leading provider of enterprise data center services, delivering secure, reliable, and flexible colocation, cloud, network, and managed services. Net Access’ data centers allow its customers to focus on their core strengths, without the need to operate the underlying infrastructure. Our team is made up of innovative, dedicated professionals that strive to provide outstanding service that aligns with our mantra, “taking care of the customer for life”. Since our inception in 1995, Net Access has become a leading data center colocation, cloud, hosting, and internet service provider, serving thousands of local and international businesses, educational institutions and government customers. Net Access operates three enterprise level SSAE 16 audited and PCI DSS compliant data centers in New Jersey. These facilities are designed specifically to provide a stable foundation needed to build and grow your infrastructure today and in the future, all while increasing operational efficiencies and lowering risk. In addition, Net Access maintains its own IP network between all its data centers and major carrier hotels. In addition to leveraging our highly capable and reliable data center infrastructure, Net Access provides customers with a wide array of cloud and internet services to help build their perfect scenario. From cloud services including public, private and hybrid cloud computing, cloud storage, cloud data backup, and web/email hosting, to network services including Ethernet, and IP transit, we can provide as little or as much of the services your company needs in today’s complex IT environment. Net Access’ experienced Operations Center staff monitors and maintains our infrastructure 24 x 7 x 365 onsite in each data center, with the ability to provide and manage our customers’ infrastructure as needed utilizing our managed services team. We provide technology solutions for small businesses and global enterprises alike. Customers choose Net Access because of our fair pricing, superior facilities, excellent service and reliability, and continuing drive to create and deploy innovative services that meet our client’s needs now and into the future. If reliability, trustworthiness, expertise and innovation are what your business seeks, then Net Access is your trusted business partner.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.